JB Chemicals & Pharmaceuticals’ (JBCPL) Q4FY23 performance was below our expectations due to seasonality in base portfolio of India and M&A-led surge in cost. M&A in India and capacity addition for CMO have lifted sales contribution of these margin-lucrative segments to 65% (55% in FY20).